fda import alert green list glp-1 semaglutide tirzepatide 2025 unveils new safeguard in battle over popular weight-loss drugs FDA creates "green list" to

That can reduce effectiveness or cause irritation

Several pharmaceutical companies are working on drugs that target nicotine receptors in the brain, in the hope that they can replicate the cognitive uptick that smokers get from cigarettes

Significant acute reductions in appetite and food intake were initially observed after intravenous (IV) administration of GLP-1 both in healthy individuals and in patients with T2D

Motivation-based wellness program participation and prior authorization are required before drug coverage

Individual factorslactation duration, dosing, maternal health prioritiesrequire nuanced discussion with your healthcare team to weigh benefits against theoretical risks